Kite Pharma Wants Fed. Circ. To Nix Juno's $1.2B Patent Win

Law360 (September 1, 2020, 9:46 PM EDT) -- Gilead unit Kite Pharma is asking the Federal Circuit to wipe out a $1.2 billion judgment in Juno Therapeutics Inc.'s favor in a patent case over Kite's cancer treatment Yescarta, saying the judgment "reward[s] Juno for Kite's success in solving the very problems Juno could not."

In a brief Monday, Gilead's Kite Pharma Inc. urged the appeals court to look into a California federal court's decision in April to award $1.2 billion to Juno and Sloan Kettering after a jury found that Kite willfully infringed Juno's patent for a cancer immunotherapy.

Kite argued that Juno's patent did not cover Kite's Yescarta...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!